Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing compound used for reducing deep abdominal fat in patients with lipodystrophy (abnormal fat distribution). It is FDA-approved and marketed as Egrifta, specifically targeting visceral fat accumulation.
Verified sources for Tesamorelin
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of Tesamorelin
Stimulates growth hormone release from the pituitary, promoting targeted lipolysis in visceral fat depots and improving metabolic markers.
Binds to GHRH receptors on pituitary somatotrophs, triggering growth hormone synthesis and pulsatile release.
Increases insulin-like growth factor 1 (IGF-1) levels, mediating anabolic and lipolytic effects.
Preferentially reduces visceral adipose tissue (VAT), targeting metabolically harmful deep abdominal fat.
Minimal effect on subcutaneous fat, specifically addressing central adiposity.
Reduces liver fat (hepatic steatosis) and improves liver enzymes (ALT, AST), with benefits for liver health.
Enhances triglyceride profiles in responders, improving metabolic markers.
Increases muscle density (proposed), which may improve muscle quality independent of quantity changes
Read Full Tesamorelin Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Growth Hormone / IGF-1 Axis
